The rapid uptake of direct-acting antiviral therapy to treat Hepatitis C virus has been credited with an estimated 30% reduction in deaths from advanced liver disease but not every infected patient is reaping the benefits of this recent treatment advance, an Australian study reveals.

Despite a relatively high treatment uptake among those with recent drug dependence, other key patient populations such as the baby boomer generation are falling through the cracks, the research shows.